Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.